Toronto, Ontario–(Newsfile Corp. – October 8, 2020) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. (“Orpheus”) are pleased to announce the recent award of a Mitacs Elevate research internship program . The project proposal has been peer-reviewed and approved in late September for matching funds for a Postdoctoral Fellowship.
Therma and Orpheus are conducting feasibility testing of CoviSafe™. Additional biological molecules are now being added as part of our screening platform, which may allow us to fill the gap in the current screening methods to detect the COVID-19 virus in asymptomatic subjects suspected of encountering COVID-19 positive individuals.
Dr. Saeid Babaei, Orpheus’ CEO, commented, “We are excited to expand our research collaboration with our academic collaborators with support from the Mitacs research internship program. This funding will allow us the necessary resources to complete the basic understanding of SARS-CoV-2 mode of action and allow us to design the most optimal biological candidates.”
Rob Fia, Therma CEO, commented, “We are pleased with the progress made on building the foundation of our rapid test supported by a strong scientific team and powerful biological platform offered by Orpheus and its academic collaborators. We look forward to reporting to investors in the near future once our feasibility work on CoviSafe™ is completed.”
Mitacs is a not-for-profit organization that fosters growth and innovation in Canada by solving business challenges with research solutions from academic institutions. Mitacs is funded by the Government of Canada, the Governments of Alberta, British Columbia, New Brunswick, Newfoundland and Labrador, Nova Scotia, Quebec and Saskatchewan, and Innovation PEI and Research Manitoba.